Hot trades in pre-market US stocks: Up 5.25% in pre-market, Julong trading actively, market sentiment is high but volatility needs to be cautious

Popular Pre-Market Trades in US Stocks Julong, up 5.25% in pre-market trading, has no significant news recently. Trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Top Gainers in Pre-Market US Stocks Theriva Biologics is up 101.09% in pre-market trading. Based on recent key news: On April 17, Theriva Biologics announced that it will present additional data from its VIRAGE Phase 2B clinical trial at the AACR 2026 Annual Meeting. The trial involves the application of VCN-01 in metastatic pancreatic cancer, demonstrating improved effects when VCN-01 is used in combination with gemcitabine/albumin-bound paclitaxel. This news significantly boosted the stock price. On April 17, the company plans to conduct a low-dose study to test whether more frequent and extended administration of VCN-01 can further improve outcomes. This move shows the company's confidence in its product, further boosting market sentiment. On April 17, results from the VIRAGE Phase 2B clinical trial showed that patients treated with VCN-01, especially those with liver metastases, exhibited better overall survival and progression-free survival. These results enhanced market confidence in the potential of VCN-01, driving the stock price up. The biotechnology sector has been active recently, with investors focusing on new drug development progress. Psyence Biomedical is up 88.55% in pre-market trading. Based on recent key news: On April 17, Psyence Biomedical announced its pharmaceutical-grade psychedelic drug NPX-5 for clinical trials, driving the stock price up. The company's CEO stated that this move will accelerate the expansion of clinical infrastructure to support ongoing patient medication, with the stock price rising 69.85% in pre-market trading. Source: GlobeNewswire On April 18, U.S. President Trump signed an executive order to expedite research and approval processes for psychedelic therapies, focusing on drugs like ibogaine, which boosted the stock prices of related companies. Source: Reuters On April 17, PsyLabs received federal licensing to support global distribution and clinical projects, with the stock price rising 40.72%. Source: Nasdaq Industry policy supports psychedelic drug research, making the market active. Clearmind Medicine is up 54.25% in pre-market trading. Based on recent key news: On April 19, U.S. President Trump signed an executive order to expedite research and approval processes for psychedelic therapies. This initiative aims to help veterans suffering from severe mental illnesses by providing new treatment options. Clearmind Medicine has gained market attention due to its research in the field of psychedelic drugs, leading to a significant increase in stock price. Changes in psychedelic therapy policies have sparked market interest